Clinical Outcomes of Ketamine Therapy for Depression, Anxiety, and PTSD in Post-TBI Patients
European Psychiatry June 1, 2026 W. Aldulaimy, A. Shah
A retrospective chart review of 35 adults with traumatic brain injury (TBI) and treatment-resistant depression and PTSD found that ketamine, administered via intramuscular injection, intranasal esketamine, or oral dissolving tablets, was associated with large reductions in depression, anxiety, and PTSD symptoms. Response rates reached 72% and remission 45%, with initial improvement within 5-10 days. Parenteral routes (IM and intranasal) outperformed oral due to better bioavailability. Adverse events were mild and transient, suggesting ketamine may be a viable option for this population.